News
AVAI
0.160
-5.10%
-0.009
Weekly Report: what happened at AVAI last week (0720-0724)?
Weekly Report · 7h ago
Stocks in play: Avai Bio Inc
Barchart · 5d ago
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
PR Newswire · 6d ago
Avai Bio, Austrianova reach deal with partner to supply insulin-producing cells for Insulinova diabetes therapy
PUBT · 6d ago
AVAÍ BIO AND AUSTRIANOVA REACH AGREEMENT FOR INSULIN-PRODUCING CELLS WITH INTERNATIONALLY ACCLAIMED PARTNER TO ADVANCE DIABETES THERAPY
Reuters · 6d ago
Weekly Report: what happened at AVAI last week (0713-0717)?
Weekly Report · 07/20 09:16
Avai Bio FY26 net loss widens 53% to USD 1.75 million
PUBT · 07/14 19:20
Weekly Report: what happened at AVAI last week (0706-0710)?
Weekly Report · 07/13 09:16
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
PR Newswire · 07/08 13:00
Weekly Report: what happened at AVAI last week (0629-0703)?
Weekly Report · 07/06 09:17
Avai Bio Delays Annual SEC Filing
TipRanks · 06/30 12:15
Avai Bio delays filing annual report for year ended March 31, 2026
PUBT · 06/30 11:20
Weekly Report: what happened at AVAI last week (0622-0626)?
Weekly Report · 06/29 09:16
Weekly Report: what happened at AVAI last week (0615-0619)?
Weekly Report · 06/22 09:18
Weekly Report: what happened at AVAI last week (0608-0612)?
Weekly Report · 06/15 09:18
Weekly Report: what happened at AVAI last week (0601-0605)?
Weekly Report · 06/08 09:17
Weekly Report: what happened at AVAI last week (0525-0529)?
Weekly Report · 06/01 09:18
Weekly Report: what happened at AVAI last week (0518-0522)?
Weekly Report · 05/25 09:19
Stocks in play: Avai Bio Inc
Barchart · 05/20 13:22
More
Webull provides a variety of real-time AVAI stock news. You can receive the latest news about AVAI BIO through multiple platforms. This information may help you make smarter investment decisions.
About AVAI
Avai Bio, Inc., formerly Avant Technologies, Inc., is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing cell-based therapies. The Company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an a-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. It has secured Joint Venture and Licensing Agreements to develop both cell lines. Its diabetes program is focused on developing an insulin-producing cell line, then encapsulating those cells inside using SGAustria's Cell-in-a-Box technology to create a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes. The Company is partnering with biotech firms, universities, scientists, and clinicians to uncover solutions for diverse healthcare challenges.